Jupiter Asset Management Ltd. cut its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 97.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,719 shares of the biopharmaceutical company’s stock after selling 350,236 shares during the quarter. Jupiter Asset Management Ltd.’s holdings in Gilead Sciences were worth $672,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank Julius Baer & Co. Ltd Zurich boosted its stake in shares of Gilead Sciences by 98,797.6% in the second quarter. Bank Julius Baer & Co. Ltd Zurich now owns 394,005,889 shares of the biopharmaceutical company’s stock valued at $30,366,034,000 after purchasing an additional 393,607,491 shares during the period. Arrowstreet Capital Limited Partnership boosted its position in shares of Gilead Sciences by 324.8% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after acquiring an additional 13,764,169 shares in the last quarter. Norges Bank acquired a new position in shares of Gilead Sciences during the 4th quarter worth about $1,115,186,000. Moneta Group Investment Advisors LLC raised its position in shares of Gilead Sciences by 96,759.8% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock worth $868,046,000 after acquiring an additional 10,100,755 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its stake in Gilead Sciences by 70.6% during the first quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock worth $921,006,000 after purchasing an additional 6,410,047 shares during the last quarter. Hedge funds and other institutional investors own 82.33% of the company’s stock.
Gilead Sciences Price Performance
Gilead Sciences stock opened at $75.45 on Monday. The company has a quick ratio of 1.20, a current ratio of 1.34 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $94.01 billion, a PE ratio of 16.19, a P/E/G ratio of 1.00 and a beta of 0.32. The firm’s 50-day simple moving average is $76.82 and its 200 day simple moving average is $77.26. Gilead Sciences, Inc. has a 52 week low of $72.87 and a 52 week high of $89.74.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a yield of 3.98%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 64.38%.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Bank of America raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $88.00 to $95.00 in a report on Friday, September 8th. Leerink Partnrs reissued a “market perform” rating on shares of Gilead Sciences in a report on Wednesday, October 11th. Deutsche Bank Aktiengesellschaft started coverage on shares of Gilead Sciences in a report on Thursday, November 9th. They issued a “hold” rating and a $75.00 target price on the stock. Barclays decreased their price target on shares of Gilead Sciences from $81.00 to $80.00 and set an “equal weight” rating for the company in a research note on Monday, July 24th. Finally, Piper Sandler reduced their target price on shares of Gilead Sciences from $105.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, July 24th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences has an average rating of “Hold” and an average price target of $88.22.
Insiders Place Their Bets
In other Gilead Sciences news, insider Merdad Parsey sold 1,501 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $76.99, for a total value of $115,561.99. Following the completion of the sale, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Andrew D. Dickinson sold 5,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 17th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the sale, the chief financial officer now directly owns 104,003 shares of the company’s stock, valued at $8,320,240. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Merdad Parsey sold 1,501 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $76.99, for a total transaction of $115,561.99. Following the transaction, the insider now directly owns 70,130 shares of the company’s stock, valued at approximately $5,399,308.70. The disclosure for this sale can be found here. 0.16% of the stock is owned by corporate insiders.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis.
- Five stocks we like better than Gilead Sciences
- Find and Profitably Trade Stocks at 52-Week Lows
- 2 stocks that under-promised and over-delivered on their earnings
- What Are Growth Stocks and Investing in Them
- 2 overlooked stocks that crushed earnings but traded lower
- Manufacturing Stocks Investing
- 3 stocks that crushed earnings estimates and still tanked
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.